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**INTRODUCTION:** Chylothorax is an accumulation of chyle in the pleural cavity typically from a breach in the integrity of the thoracic duct whose etiology can be classified into three broad categories: spontaneous (non-traumatic), traumatic, and idiopathic. Dasatinib-related pleural effusions have been reported in 28-35% of patients (1); however, chylothorax is a rare complication and there are less than 10 cases described in the literature (2,3). We describe a case in which our patient developed a chylothorax four months after starting dasatinib therapy for chronic myeloid leukemia.

**CASE PRESENTATION:** A 71 year old male with history of chronic myeloid leukemia presented to our hospital with new onset shortness of breath. Of note, patient received an allogeneic sibling-matched stem cell transplant approximately twenty years prior, but relapsed and was started on daily dasatinib therapy four months prior to presentation. The patient reported a two-week history of cough with bloody sputum, low grade fevers, and shortness of breath with exertion. He denied trauma, recent surgery, or tuberculosis exposure. Work-up revealed a respiratory viral panel positive for coronavirus and a large right pleural effusion with right middle lobe and lower lobe compressive atelectasis on the CT chest. The patient underwent diagnostic and therapeutic thoracentesis. Pleural fluid was cream colored, exudative per Light\'s criteria with predominance of lymphocytes and had a triglyceride level of \>500mg/dl. Cytology was negative for malignancy. Therapy with dasatinib was stopped and the patient clinically improved. Follow up imaging is pending at this time.

**DISCUSSION:** Dasatinib is a second generation potent and efficacious oral tyrosine kinase inhibitor, frequently used for treatment resistant chronic myeloid leukemia and acute lymphocytic leukemia (2). Mechanism of dasatinib-related pleural effusions is postulated to be due to immune mediation, increased vascular permeability from tyrosine kinase inhibition, and decreased interstitial pressure due to inhibition of platelet derived growth factor (1,3). Dasatinib-related chylothorax is a rare poorly understood phenomenon. The chylous effusions are typically lymphocyte-predominant exudative effusions, as seen in our patient. To date, dasatinib is the only known drug to be implicated in chylous effusions (2). Resolution of dasatinib-related chylothorax has been described with both dose discontinuation and dose reduction (3).

**CONCLUSIONS:** Dasatinib therapy should be considered in the etiology of pleural effusion and chylothorax in patients with chronic myelogenous leukemia.
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